Delcath Systems/DCTH

$4.87

3.72%
-
1D1W1MYTD1YMAX

About Delcath Systems

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Ticker

DCTH

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Gerard Michel

Employees

76

Headquarters

Queensbury, United States

Delcath Systems Metrics

BasicAdvanced
$113.84M
Market cap
-
P/E ratio
-$2.98
EPS
0.60
Beta
-
Dividend rate
$113.84M
0.60003
$7.99
$2.25
202.25K
2.259
2.057
64.334
-26.53%
-168.85%
-961.44%
-377.02%
55.129
6.456
7.216
-24.08%
30.66%
7.85%

What the Analysts think about Delcath Systems

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
277.82% upside
High $22.00
Low $13.00
$4.87
Current price
$18.40
Average price target

Delcath Systems Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,220% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$500K
25%
Net income
$-11.1M
-45.32%
Profit margin
-2,220%
-56.26%

Delcath Systems Earnings Performance

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-
-
-
-
-
Expected
$0.00
$0.00
$0.00
$0.00
-$0.47
Surprise
-
-
-
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Delcath Systems stock?

Delcath Systems (DCTH) has a market cap of $113.84M as of April 21, 2024.

What is the P/E ratio for Delcath Systems stock?

The price to earnings (P/E) ratio for Delcath Systems (DCTH) stock is 0 as of April 21, 2024.

Does Delcath Systems stock pay dividends?

No, Delcath Systems (DCTH) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Delcath Systems dividend payment date?

Delcath Systems (DCTH) stock does not pay dividends to its shareholders.

What is the beta indicator for Delcath Systems?

Delcath Systems (DCTH) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Delcath Systems stock price target?

The target price for Delcath Systems (DCTH) stock is $18.4, which is 277.82% above the current price of $4.87. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Delcath Systems stock

Buy or sell Delcath Systems stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing